Working… Menu

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01611766
Recruitment Status : Recruiting
First Posted : June 5, 2012
Last Update Posted : February 27, 2018
Fudan University
Zhejiang Cancer Hospital
Shanghai Zhongshan Hospital
Sun Yat-sen University
Information provided by (Responsible Party):
Shanghai Gynecologic Oncology Group

Brief Summary:
The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian cancer.

Condition or disease Intervention/treatment Phase
Ovarian Epithelial Cancer Recurrent Fallopian Tube Carcinoma Primary Peritoneal Carcinoma Procedure: Secondary Cytoreductive Surgery Drug: Salvage Chemotherapy Phase 3

Detailed Description:
The primary objective of this study is to compare overall survival (OS) in patients with platinum-sensitive recurrent ovarian cancer with a positive SCR score randomized to secondary cytoreductive surgery followed by chemotherapy versus chemotherapy alone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 356 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial
Study Start Date : January 2011
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: secondary cytoreductive surgery
SCR followed by chemotherapy
Procedure: Secondary Cytoreductive Surgery
Complete Cytoreduction
Other Name: Debulking Surgery

Drug: Salvage Chemotherapy
Active Comparator: Salvage Chemotherapy
platinum-based chemotherapy
Drug: Salvage Chemotherapy

Primary Outcome Measures :
  1. Overall survival [ Time Frame: Up to 36 months after last patient randomized ]

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: Progression-free survival is defined as interval between date of randomization and 2nd relapse/progression or death (whatever occurs first), assessed up to 36 months. ]
  2. Quality of Life [ Time Frame: Baseline, 6, 12, 24 and 60 months after randomization ]
  3. Complications incidence [ Time Frame: From the operation until after 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age at recurrence ≥ 18 years
  • Patients with platinum-sensitive, first relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (EOC, PPC, FTC), which is defined as those with treatment -free interval of 6 months or more.
  • A complete secondary cytoreduction predicting score, iMODEL [Tian WJ, Ann Surg Oncol 2012,19(2):597-604]<=4.7, including FIGO stage (0 or 0.8); residual disease after primary surgery (0 or 1.5); Progression-free interval (0 or 2.4); PS ECOG (0 or 2.4); Ca125 (0 or 1.8); and ascites at recurrence (0 or 3.0). If PI and CO-PI reach consensus that the recurrent tumor detected by PET/CT could be completely resected, the index of CA125 could be scored as 0. (Revised on 09/30/2013)
  • Assessed by the experienced surgeons, complete resection of all recurrent disease is possible. If single lesion outside the peritoneal cavity can be resected, MRI/CT or PET/CT scan should be performed to exclude simultaneous intra-abdominal lesions.
  • Patients who have given their signed and written informed consent and their consent.

Exclusion Criteria:

  • Patients with borderline tumors as well as non-epithelial tumors.
  • Patients for interval-debulking, or for second-look surgery, or palliative surgery planned.
  • Impossible to assess the resectability or evaluate the score. Radiological signs suggesting complete resection is impossible.
  • More than one prior chemotherapy.
  • Second relapse or more
  • Patients with second or other malignancies who have been treated by surgery, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected.
  • Progression during chemotherapy or recurrence within 6 months after first-line therapy
  • Any contradiction not allowing surgery and/or chemotherapy

    1. Accompanied by hypoxia serious chronic obstructive pulmonary disease
    2. Uncontrolled hypertension, cerebrovascular accident/ Stroke, myocardial infarct, unstable angina, untreated thrombosis, chronic congestive heart failure, or serious arrhythmia in need of medicine.
    3. Severe hepatitis, history of liver disease, nephrotic syndrome, renal insufficiency
    4. Active ulcer history, abdominal wall fistula, perforation of gastrointestinal tract, or Intra-abdominal abscess, or simultaneously apply treatment/prevent ulcers therapy.
    5. Uncontrolled diabetes
    6. Uncontrolled epilepsy need long-term antiepileptic treatment.
  • Any medication induced considerable risk of surgery, e.g. estimated bleeding due to oral anticoagulating agents, or bevacizumab)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01611766

Layout table for location contacts
Contact: Xiao Huang, MD, PhD +862164175590
Contact: Yuting Luan, RN +862164175590;

Layout table for location information
China, Guangdong
Sun Yat-sen University Cancer Center Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Jihong Jiu, MD, PhD    86 20 87343088   
China, Shanghai
Fudan University Cancer Hospital Recruiting
Shanghai, Shanghai, China, 200032
Contact: Xiao Huang, MD,PhD    +862164175590   
Principal Investigator: Rongyu Zang, MD,PhD         
Shanghai Zhongshan Hospital Recruiting
Shanghai, Shanghai, China, 200032
Contact: Rong Jiang, MD    86 21 64041990 ext 2905   
China, Zhejiang
Zhejiang Cancer Hospital Recruiting
Hangzhou, Zhejiang, China, 310022
Contact: Jianqing Zhu, MD    86 571 8822222   
Sponsors and Collaborators
Shanghai Gynecologic Oncology Group
Fudan University
Zhejiang Cancer Hospital
Shanghai Zhongshan Hospital
Sun Yat-sen University
Layout table for investigator information
Principal Investigator: Rongyu Zang, MD,PhD Shanghai Gynecologic Oncology Group

Additional Information:
Layout table for additonal information
Responsible Party: Shanghai Gynecologic Oncology Group Identifier: NCT01611766     History of Changes
Other Study ID Numbers: V02_2010_10
SGOG OV2 ( Other Identifier: SGOG )
First Posted: June 5, 2012    Key Record Dates
Last Update Posted: February 27, 2018
Last Verified: July 2016
Keywords provided by Shanghai Gynecologic Oncology Group:
secondary cytoreductive surgery
Ovarian Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders